Natera INC. and University of California, San Francisco (UCSF) have entered a research agreement to analyse and study the DNA markers of kidney transplant rejection.
According to the agreement, the partners will investigate the level of donor-derived, cell-free DNA (dd-cfDNA) in hundreds of banked plasma samples collected at UCSF, using Natera’s Proprietary PCR platform and algorithms.
The agreement enables the partners to analyse whether the routine measurements of dd-cfDNA can predict the organ injury and therefore improve clinical outcomes.
Evelo Biosciences has entered a research agreement with Mayo Clinic to further develop novel immune-microbiome cancer therapies.
According to the agreement, the two partners will jointly work on isolation and characterisation of cancer-associated bacteria from patient’s samples and tumour biopsies for the development of onco-microbials to treat cancer.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Attenua INC. has entered a definitive agreement to acquire oral Neuronal Nicotinic Receptor assets from Catalyst Biosciences.
Pursuant to the agreement, Attenua will pay an upfront payment of $1m and up to $105m as development, regulatory and commercial milestone payments, and royalties to Catalyst Biosciences.
The transaction enables Attenua to expand its businesses and Catalyst Bioscienes to realise additional value for a subset of the non-core assets.
Protagonist Therapeutics, a biotechnology company, has announced an initial public offering (IPO) of 5,835,000 of its common stock shares. The company expects to raise gross proceeds of up to $75.8m through the offering.
The company plans to invest the funds partly to advance the phase IIb clinical trials of PTG-100, to complete investigational new drug (IND) enabling studies for PTG-200 and PTG-300 and to use the remaining for working capital and general corporate purposes.
Avrobio INC. has raised $25m in a series A venture financing round, which was co-led by Atlas Venture L.P. Clarus Venture LLC, and SV Life Sciences Advisers LLP.
The company plans to use the proceeds to further develop the clinical-stage programmes for fabry disease and acute myeloid leukaemia, as well as expand its pipeline for rare diseases and solid and liquid cancers.
Image: Evelo Biosciences has entered a research agreement with Mayo Clinic. Photo: Courtesy of Nephron.